Enliven Treateutics(ELVN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ELVN Enliven Treateutics

休市中 06-18 16:00:00 EDT

45.10

+0.24

+0.53%

盘后45.10

+0.000.00%

18:50 EDT

最高45.72	最低44.22	成交量244.98万
今开45.01	昨收44.86	日振幅3.34%
总市值31.50亿	流通市值24.07亿	总股本6,984万
成交额1.10亿	换手率4.59%	流通股本5,336万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":45.1,"timestamp":1781812800000,"preClose":44.86,"halted":0,"volume":2449816,"hourTrading":{"tag":"盘后","latestPrice":45.1,"preClose":45.1,"latestTime":"18:50 EDT","volume":185647,"amount":8372700.3585,"timestamp":1781823026858,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005349977708426259,"floatShares":53361200,"shares":69838300,"eps":-1.654577,"marketStatus":"休市中","change":0.24,"latestTime":"06-18 16:00:00 EDT","open":45.01,"high":45.72,"low":44.22,"amount":110367535.200312,"amplitude":0.033437,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.654577,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":44.86,"preHourTrading":{"tag":"盘前","latestPrice":44.98,"preClose":44.86,"latestTime":"09:29 EDT","volume":427,"amount":19231.4395,"timestamp":1781789399999,"change":0.12,"changeRate":0.002675,"amplitude":0.050825},"postHourTrading":{"tag":"盘后","latestPrice":45.1,"preClose":45.1,"latestTime":"18:50 EDT","volume":185647,"amount":8372700.3585,"timestamp":1781823026858,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6448203037788005,"impliedVol":0.7372,"impliedVolPercentile":0.6614},"requestUrl":"/m/hq/s/ELVN/wiki","defaultTab":"wiki","newsList":[{"id":"1144601160","title":"Enliven Treateutics就Enable-2试验80毫克每日一次III期剂量及二线以上患者人群与FDA达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1144601160","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144601160?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:02","pubTimestamp":1781179340,"startTime":"0","endTime":"0","summary":"Enliven Treateutics宣布，已就关键III期临床试验Enable-2的研究方案与美国食品药品监督管理局达成重要共识。双方确认了80毫克每日一次作为试验剂量，并明确了试验将针对既往接受过至少二线治疗的特定患者人群。这一进展为后续临床开发路径奠定了监管基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189324002","title":"Enliven Therapeutics公布161名患者安全性数据：中位治疗周期35周，安全性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1189324002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189324002?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:01","pubTimestamp":1781179295,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics公布了一项涉及161名患者的临床数据，结果显示其治疗药物展现出良好的安全性特征。数据显示，患者的中位治疗持续时间已达到35周。这一积极的安全性数据为后续的临床开发提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129363356","title":"Enliven Therapeutics公布一期临床积极数据更新，并就三期试验关键设计要素与FDA达成共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1129363356","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129363356?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:00","pubTimestamp":1781179240,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics 今日宣布，其针对关键候选药物的一期临床研究数据获得积极更新。与此同时，公司已与美国食品药品监督管理局（FDA）就即将开展的三期临床试验的关键设计要素达成重要共识。\n此次公布的数据进一步验证了该疗法的初步疗效与安全性特征。与监管机构达成的共识，为后续三期试验的顺利推进奠定了坚实基础，标志着该药物研发进程迈入关键新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175390416","title":"Enliven Treateutics 向SEC提交文件 将授权普通股增至2亿 自2026年6月9日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1175390416","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175390416?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:02","pubTimestamp":1781085760,"startTime":"0","endTime":"0","summary":"Enliven Treateutics 已向美国证券交易委员会提交文件，宣布将其授权普通股数量增至2亿股。此项变更将于2026年6月9日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136527442","title":"Enliven Therapeutics宣布在EHA 2026大会上作口头报告，展示ELVN-001治疗CML的额外积极1期临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1136527442","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136527442?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:57","pubTimestamp":1778594236,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics公司宣布，将在2026年欧洲血液学协会（EHA）大会上进行一项口头报告，重点展示其候选药物ELVN-001用于治疗慢性粒细胞白血病（CML）的额外积极1期临床试验数据。此次报告将进一步呈现该药物在早期临床研究中的积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183331226","title":"Enliven Therapeutics公布2025年第四季度及全年财务业绩，并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1183331226","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183331226?lang=zh_cn&edition=full","pubTime":"2026-03-04 05:06","pubTimestamp":1772572000,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics（股票代码：ELVN）近日披露了其2025财年第四季度及全年的财务报告，同时向市场通报了公司最新的业务动态。此次公布的数据涵盖了公司在关键财务指标上的表现，以及研发管线、战略合作等方面的进展，为投资者提供了全面的运营概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603639391","title":"Enliven Therapeutics, Inc.盘中异动 早盘大幅上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603639391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603639391?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:31","pubTimestamp":1768318304,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日23时31分，Enliven Therapeutics, Inc.股票出现异动，股价急速上涨5.03%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，Xtl生物制药、Decoy Therapeutics Inc.、Briacell Therapeutics Corp.涨幅较大，Decoy Therapeutics Inc.、Scisparc Ltd.、Briacell Therapeutics Corp.较为活跃，换手率分别为1285.20%、1147.30%、306.07%，振幅较大的相关个股有Xtl生物制药、Lexaria Bioscience Corp C/Wts 14/01/2026 、Decoy Therapeutics Inc.，振幅分别为93.69%、67.92%、41.72%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的生物制药公司，专注于小分子治疗药物的发现和开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011323314497a1a969&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011323314497a1a969&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","LENZ","BK4139","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157497283","title":"Enliven Treateutics持续为2026年启动ELVN-001三期临床试验及商业化铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=1157497283","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157497283?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:07","pubTimestamp":1767794873,"startTime":"0","endTime":"0","summary":"Enliven Treateutics公司正稳步推进其核心管线ELVN-001的研发进程，为预计于2026年启动的关键性三期临床试验做充分准备，并同步规划该候选药物的未来商业化路径。公司此举旨在加速将这一创新疗法推向市场，为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518031273","title":"Enliven Therapeutics, Inc.盘中异动 急速跳水5.10%报19.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518031273","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518031273?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:24","pubTimestamp":1741616661,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时24分，Enliven Therapeutics, Inc.股票出现异动，股价急速下挫5.10%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3410.94%、721.77%、415.50%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc，振幅分别为41.36%、40.24%、39.34%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222421a26a38fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222421a26a38fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517929888","title":"Enliven Therapeutics, Inc.盘中异动 股价大涨5.07%报20.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517929888","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517929888?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:33","pubTimestamp":1741206800,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时33分，Enliven Therapeutics, Inc.股票出现异动，股价大幅拉升5.07%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.91%。其相关个股中，Chimerix, Inc.、Geovax Labs Inc C/Wts 29/09/2025、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为975.81%、319.18%、318.25%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Geovax Labs Inc C/Wts 29/09/2025，振幅分别为82.59%、54.27%、51.93%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306043321a2612b77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306043321a2612b77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELVN","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516639446","title":"Enliven Therapeutics, Inc.盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639446","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516639446?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:34","pubTimestamp":1741034058,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时34分，Enliven Therapeutics, Inc.股票出现异动，股价快速跳水5.04%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 、Biocardia, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为215.29%、187.44%、163.53%，振幅较大的相关个股有Radiopharm Theranostics Limited、Entero Therapeutics Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为119.50%、70.53%、64.88%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043418abe697c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043418abe697c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELVN","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514491760","title":"Enliven Therapeutics, Inc.盘中异动 股价大跌5.34%报20.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514491760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514491760?lang=zh_cn&edition=full","pubTime":"2025-02-26 04:52","pubTimestamp":1740516724,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日04时52分，Enliven Therapeutics, Inc.股票出现异动，股价大幅跳水5.34%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为2127.72%、1185.08%、1025.80%，振幅较大的相关个股有Organovo Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为241.19%、224.55%、127.49%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045205989291a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045205989291a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELVN","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509237713","title":"Enliven Therapeutics, Inc.盘中异动 股价大涨5.18%报23.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509237713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509237713?lang=zh_cn&edition=full","pubTime":"2025-02-06 02:28","pubTimestamp":1738780135,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日02时28分，Enliven Therapeutics, Inc.股票出现波动，股价急速上涨5.18%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.10%。其相关个股中，Transcode Therapeutics, Inc.、Pasithea Therapeutics Corp.、Celularity Inc C/Wts 16/07/2026 涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4578.82%、2279.33%、1708.47%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 ，振幅分别为122.81%、99.51%、59.58%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206022856abc3afb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206022856abc3afb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508993094","title":"Enliven Therapeutics, Inc.盘中异动 急速上涨5.03%报22.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508993094","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508993094?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:56","pubTimestamp":1738346166,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日01时56分，Enliven Therapeutics, Inc.股票出现异动，股价急速上涨5.03%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.73%。其相关个股中，Cyclerion Therapeutics, Inc.、Metsera, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.、Silexion Therapeutics Corp较为活跃，换手率分别为2641.19%、1991.63%、193.33%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.，振幅分别为98.89%、80.00%、56.30%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201015606abbe5eae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201015606abbe5eae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELVN","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505201986","title":"Enliven Therapeutics, Inc.盘中异动 大幅上涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505201986","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505201986?lang=zh_cn&edition=full","pubTime":"2025-01-22 01:18","pubTimestamp":1737479904,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日01时18分，Enliven Therapeutics, Inc.股票出现波动，股价大幅拉升5.17%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.88%。其相关个股中，Camp4 Therapeutics Corporation、Genelux Corporation、Channel Therapeutics Corporation涨幅较大，Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃，换手率分别为770.28%、503.77%、187.26%，振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.，振幅分别为96.32%、41.33%、38.48%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122011824a22a7a46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122011824a22a7a46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","ELVN","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503250713","title":"Enliven Therapeutics, Inc.盘中异动 急速跳水5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503250713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503250713?lang=zh_cn&edition=full","pubTime":"2025-01-15 02:12","pubTimestamp":1736878345,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日02时12分，Enliven Therapeutics, Inc.股票出现异动，股价快速下跌5.75%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，Eterna Therapeutics Inc.、Seastar Medical Holding Corp C/Wts 28/10/2027 、Jasper Therapeutics Inc C/Wts 24/09/2026 涨幅较大，Eterna Therapeutics Inc.、Phio Pharmaceuticals Corp.、Soligenix, Inc.较为活跃，换手率分别为1014.80%、558.98%、415.29%，振幅较大的相关个股有Eterna Therapeutics Inc.、Matinas Biopharma Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为170.74%、69.81%、69.33%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115021225abaadddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115021225abaadddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELVN","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502860491","title":"Enliven Therapeutics, Inc.盘中异动 早盘快速跳水5.47%报22.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502860491","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502860491?lang=zh_cn&edition=full","pubTime":"2025-01-10 23:08","pubTimestamp":1736521710,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日23时08分，Enliven Therapeutics, Inc.股票出现波动，股价快速下挫5.47%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.32%。其相关个股中，Conduit Pharmaceuticals Inc.、Jasper Therapeutics Inc C/Wts 24/09/2026 、Precision Biosciences, Inc.涨幅较大，Zyversa Therapeutics, Inc.、Conduit Pharmaceuticals Inc.、Precision Biosciences, Inc.较为活跃，换手率分别为1096.97%、376.22%、198.19%，振幅较大的相关个股有Conduit Pharmaceuticals Inc.、Precision Biosciences, Inc.、Zyversa Therapeutics, Inc.，振幅分别为85.00%、41.78%、37.29%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110230830aba60c68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110230830aba60c68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ELVN","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500828117","title":"Enliven Therapeutics, Inc.盘中异动 快速上涨5.23%报25.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500828117","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500828117?lang=zh_cn&edition=full","pubTime":"2025-01-03 23:02","pubTimestamp":1735916522,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日23时02分，Enliven Therapeutics, Inc.股票出现异动，股价急速上涨5.23%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Apollomics Inc C/Wts 01/04/2028 、Scorpius Holdings, Inc.、Cyclacel Pharmaceuticals, Inc.涨幅较大，Scorpius Holdings, Inc.、Cyclacel Pharmaceuticals, Inc.、Onconetix, Inc.较为活跃，换手率分别为1425.26%、1076.77%、282.68%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Cyclacel Pharmaceuticals, Inc.、Scorpius Holdings, Inc.，振幅分别为143.91%、87.11%、85.72%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103230202ab9d617c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103230202ab9d617c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELVN","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500297663","title":"Enliven Therapeutics, Inc.盘中异动 早盘股价大涨5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500297663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500297663?lang=zh_cn&edition=full","pubTime":"2025-01-02 23:54","pubTimestamp":1735833272,"startTime":"0","endTime":"0","summary":"北京时间2025年01月02日23时54分，Enliven Therapeutics, Inc.股票出现异动，股价大幅上涨5.82%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.90%。其相关个股中，Mustang Bio, Inc.、Revelation Biosciences Inc C/Wts 10/01/2027 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Revelation Biosciences, Inc.、知临集团、Mustang Bio, Inc.较为活跃，换手率分别为1133.85%、141.47%、53.99%，振幅较大的相关个股有Revelation Biosciences, Inc.、Mustang Bio, Inc.、Revelation Biosciences Inc C/Wts 10/01/2027 ，振幅分别为127.98%、113.33%、98.57%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010223543298590e78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010223543298590e78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELVN","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2494339573","title":"Enliven Therapeutics, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494339573","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494339573?lang=zh_cn&edition=full","pubTime":"2024-12-28 01:20","pubTimestamp":1735320011,"startTime":"0","endTime":"0","summary":"北京时间2024年12月28日01时20分，Enliven Therapeutics, Inc.股票出现波动，股价快速下挫5.02%。Enliven Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.53%。其相关个股中，Vor Biopharma Inc.、Abpro Holdings, Inc、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Evaxion Biotech As、Scisparc Ltd.、Neuphoria Therapeutics Inc.较为活跃，换手率分别为119.67%、57.72%、51.54%，振幅较大的相关个股有Nkgen Biotech Inc C/Wts 31/05/2028、Galectin Therapeutics Inc.、Abpro Holdings, Inc，振幅分别为147.50%、65.39%、62.45%。Enliven Therapeutics, Inc.公司简介：Enliven Therapeutics Inc 是一家临床阶段的精准肿瘤学公司，专注于发现和开发潜在的一流精准肿瘤疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412280120119851f63b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412280120119851f63b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELVN","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.enliventherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1174},{"period":"1month","weight":0.1227},{"period":"3month","weight":0.5536},{"period":"6month","weight":1.6734},{"period":"1year","weight":1.0909},{"period":"ytd","weight":1.9286}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Enliven Therapeutics, Inc.于2019年6月12日在特拉华州注册成立。这家临床阶段的生物制药公司专注于小分子治疗药物的发现与开发，旨在帮助人们不仅能够活得更长，而且能够过得更好。公司通过精准医疗的方法来解决现有和新兴的未满足需求，从而提高生存率并增强整体福祉。其发现过程结合了对经过临床验证的生物靶点的深刻见解和差异化化学，目标是设计满足这些未满足需求的疗法。通过将临床验证的靶点和特定的目标产品特征与严谨的临床试验设计及监管策略相结合，致力于开发出有效满足未满足需求的药物，提高临床和商业成功的可能性。目前，该公司正在推进 ELVN-001，并探索与其小分子开发战略相一致的多个额外研究阶段机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.026887},{"month":2,"riseRate":0.666667,"avgChangeRate":0.05311},{"month":3,"riseRate":0.666667,"avgChangeRate":0.048411},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063791},{"month":5,"riseRate":0.285714,"avgChangeRate":0.136586},{"month":6,"riseRate":0.857143,"avgChangeRate":0.048473},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.105586},{"month":8,"riseRate":0.5,"avgChangeRate":-0.03666},{"month":9,"riseRate":0.5,"avgChangeRate":0.118476},{"month":10,"riseRate":0.5,"avgChangeRate":0.124766},{"month":11,"riseRate":0.166667,"avgChangeRate":0.036396},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.10748}],"exchange":"NASDAQ","name":"Enliven Treateutics","nameEN":"Enliven Treateutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enliven Treateutics(ELVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Enliven Treateutics(ELVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Enliven Treateutics,ELVN,Enliven Treateutics股票,Enliven Treateutics股票老虎,Enliven Treateutics股票老虎国际,Enliven Treateutics行情,Enliven Treateutics股票行情,Enliven Treateutics股价,Enliven Treateutics股市,Enliven Treateutics股票价格,Enliven Treateutics股票交易,Enliven Treateutics股票购买,Enliven Treateutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enliven Treateutics(ELVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Enliven Treateutics(ELVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}